Companion Diagnostics Market Share, Key Players and Future Scope

Biotechnology Companion Diagnostics Market Size, Share, Development, Growth and Demand Forecast to 2024

Š P&S Intelligence. All rights reserved

1

Companion diagnostics offers a set of tools that facilitates biological and clinical information to the pharmaceutical companies that they have to overcome. Companion diagnostics help physicians to improve the treatment decisions for the patients depending on their response to current treatments.

Companion diagnostics approach to medication is transforming the healthcare industry by eliminating unfavorable reactions, improving treatment outcomes, and reducing the cost and time difficulties associated with conventional methods of medication. Companion diagnostic is basically a bio-analytical method designed to evaluate whether the patient will respond favorably to the specific medical treatment or not. The market is fully dependent on discovery of biomarkers, and research and development of new drugs. With the surge in research and development of targeted rehabilitations and innovation of new biomarkers for a range of conditions, the global companion diagnostics market is growing at healthy rate.

Download sample copy of this report at: https://www.psmarketresearch.com/market-analysis/companiondiagnostics-market/report-sample Several targeted drugs in association with a companion diagnostics test are developed and have reached to large numbers of consumers. Large and small biopharmaceutical companies actively develop drug diagnostic combination products which are fast to surpass traditional drugs, favoring the concept of one-size-fits-all. U.S. Food and Drug Administration (FDA) have approved companion diagnostics for lung colorectal, breast, and melanoma. Some of the companion diagnostics devices are erbitux vectibix, lynparza, gilotrif, herceptin, exjade, gleevec, zelboraf and tarceva.

Increasing scope for companion diagnostics and emerging technologies, such as next-generation sequencing (NGS), are some of the major opportunities for the global companion diagnostics market. Some of the major factors driving the growth of global companion diagnostics market are growing adoption of companion diagnostics by pharmaceutical companies and reference laboratories, regulatory bodies encouraging implementation of companion diagnostics, increasing demand and developmental of personalized medicine and rising demand for targeted cancer treatment.

Š P&S Intelligence. All rights reserved

2

Reimbursement scenario, effect of influence of advocacy groups and clinical societies, and extended developmental and approval phases are some of the factors that are restraining the growth of global companion diagnostics market. One of the major challenges for the companion diagnostics market is co-ordination in the development of drugs and diagnostics together.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/sendenquiry?enquiry-url=companion-diagnostics-market North America had the largest companion diagnostics market because of the increasing incidence of cancer and increased healthcare awareness. Whereas, Asia-Pacific is the fastest growing market of companion diagnostics owing to the strengthening healthcare services and increasing medical tourism in developing countries such as India and China.

Some of the major competitors in companion diagnostics market are Biogenex Laboratories Inc, Agilent Technologies, Inc., Abbott Laboratories, Inc., Beckman Coulter, Inc., Danaher Corporation, Myriad Genetics, Inc., Qiagen N.V., bioMĂŠrieux SA, F. Hoffmann-La Roche AG, and General Electric Company.

Read More: https://www.psmarketresearch.com/marketanalysis/companion-diagnostics-market

Š P&S Intelligence. All rights reserved

3

Disclaimer: P&S Intelligence always keeps its customers’ interests at the core while carrying out research activities. P&S Intelligence ensures the reliability and accuracy of information and data provided in its market research publications. However, the information in publications is subject to fluctuations, as it is based on primary interviews of officials from various companies or organizations. P&S Intelligence is not responsible for any incorrect data provided by the key industry players of the concerned domain. The information or analysis in P&S Intelligence publications represents opinions based on research and should not be interpreted as statements of fact. Information in this report was believed to be correct at the time of publication, but cannot be guaranteed. P&S Intelligence does not endorse any product, service, or vendor depicted in its research publications.

All intellectual properties, including trademarks and copyrights, belong to their respective owners and may be protected by copyright. Under no circumstance can these be reproduced in any form without prior written agreement of their owners.

An order for market research report is intended for internal use of the company only and not for disclosure to third parties or any other publication in general. No service, report, or part thereof provided by P&S Intelligence can be reproduced, republished, resold, revealed, distributed, circulated, or sublicensed in any medium or form now realized or hereafter become realized, including but not limited to, all forms of optical-based media, magnetic, electronic, or digital, without a written permission from Prescient & Strategic Intelligence Pvt. Ltd.

Kindly write to: enquiry@psmarketresearch.com B-13, Sector – 2, Noida, U.P. – 201301, INDIA Contact No: +91 120 4541 337 US/Canada Toll-Free: 1-888-778-7886 © P&S Intelligence. All rights reserved

4